- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT00042991
Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
Phase I/II Trial of Gefitinib and Radiation in Pediatric Patients Newly Diagnosed With Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas With Phase II Limited to Brain Stem Tumors
Tutkimuksen yleiskatsaus
Tila
Ehdot
- Hoitamaton lapsuuden aivovarren gliooma
- Hoitamaton lapsuuden anaplastinen astrosytooma
- Hoitamaton lapsuuden anaplastinen oligodendrogliooma
- Hoitamaton lapsuuden jättisoluinen glioblastooma
- Hoitamaton lapsuuden glioblastooma
- Hoitamaton lapsuuden gliomatosis Cerebri
- Hoitamaton lapsuuden gliosarkooma
- Hoitamaton lapsuuden oligodendrogliooma
Yksityiskohtainen kuvaus
PRIMARY OBJECTIVES:
I. To define the safety of gefitinib administered in conjunction with irradiation in children with newly diagnosed non-disseminated diffuse intrinsic brainstem gliomas and newly diagnosed incompletely resected supratentorial malignant gliomas (STMG) not receiving enzyme inducing anticonvulsant drugs (EIACDs).
II. To define the safety of gefitinib in children with newly diagnosed, incompletely resected STMG receiving EIACDs.
III. To assess the safety and efficacy of gefitinib given with radiation therapy in children newly diagnosed with a brainstem glioma as measured by progression-free survival and to estimate the survival distribution.
SECONDARY OBJECTIVES:
I. To compare hemodynamic magnetic resonance (MR) parameters to metabolic fludeoxyglucose F 18 (FDG)-positron emission tomography (PET) scanning and correlate both with clinical response or progression in this population.
II. To characterize the expression of ErbB1 receptors in tissue from STMG patients using immunohistochemistry and western blot assays.
III. To characterize the pharmacokinetics of gefitinib in the above patient groups and determine the effects of EIACD on the pharmacokinetics.
IV. To explore the pharmacogenetic polymorphisms for gefitinib (e.g., CYP3A4/5 and BCRP) and relate them to gefitinib pharmacokinetics and pharmacodynamics (phenotype-genotype).
OUTLINE: This is a multicenter, dose-escalation study of gefitinib (Phase I closed to accrual effective 10/27/2003). Patients are stratified according to the following:
Stratum 1A: Intrinsic brain stem glioma; not receiving concurrent enzyme-inducing anticonvulsant drugs (EIACDs) Stratum 1B: Incompletely resected supratentorial malignant gliomas (STMG); not receiving concurrent EIACDs Stratum 2: Incompletely resected STMG; receiving concurrent EIACDs.
Phase I portion (patients in strata 1A, 1B, and 2) (phase I closed to accrual effective 10/27/2003): Patients receive oral gefitinib once daily. Treatment repeats every 4 weeks for 13 courses (1 year). Patients also receive standard brain irradiation once daily, 5 days a week, for 6 weeks beginning concurrently with initiation of the first course of gefitinib. Treatment continues in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of gefitinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
Phase II portion (patients in stratum 1A): Once the MTD or the recommended Phase-II dose is determined, additional patients who have newly diagnosed brain stem gliomas (BSG) are treated at the MTD or the recommended Phase-II dose.
Patients are followed for three months after the last protocol treatment for those enrolled strictly on the phase I component. Patients contributing to the phase II portion are followed until the earliest of date of death or three years after initiation of protocol therapy.
PROJECTED ACCRUAL: Considering the seven dose levels to be investigated in three strata, where each dose level can accrue up to six patients, a total of 126 patients (42 for each strata) may be accrued for this study within 2 years. (Phase I closed to accrual effective 10/27/2003). A total of 40 patients including the patients treated at the maximum tolerated dose or the recommended Phase-II dose during Phase I will be accrued for phase II of this study within 10 months.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 2
- Vaihe 1
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Tennessee
-
Memphis, Tennessee, Yhdysvallat, 38105
- Pediatric Brain Tumor Consortium
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
Tumor:
- Phase I: newly diagnosed non-disseminated diffuse intrinsic brainstem tumor or newly diagnosed (diagnostic scan must be within 4 weeks prior to treatment initiation), incompletely resected supratentorial malignant glioma (anaplastic astrocytoma, glioblastoma multiforme or other high-grade glioma) (STMG); the STMG group must have residual tumor evident on postoperative MRI or CT
- Phase II: only newly diagnosed non-disseminated diffuse intrinsic brain stem glioma patients are eligible
- Performance status: Karnofsky or Lansky >= 50% assessed within two weeks prior to registration
Prior/concurrent therapy:
- Chemotherapy: no prior therapy allowed, including prior gefitinib treatment
- Radiation therapy (XRT): no prior therapy allowed
- Bone marrow transplant: none prior
- Anti-convulsants: patients with brain stem glioma (BSG) receiving EIACD will not be eligible; patients with STMG will be eligible for this study even if they are receiving enzyme inducting anti-convulsant drugs (EIACD) and will be stratified by use of EIACDs
- Growth factors: off all colony forming growth factor(s) > 2 weeks prior to registration (G-CSF, GM-CSF, erythropoietin)
- ANC > 1,000/ul
- Platelets > 100,000/ul (transfusion independent)
- Hemoglobin > 8g/dl (may be transfused)
- Patients may have bone marrow involvement by disease
- Creatinine < 2 x normal for age or GFR > 70 ml/min/1.73m^2
- Bilirubin < 1.5 x normal institutional normal for age
- SGPT (ALT) < 3 x institutional normal for age
- Pregnant and/or lactating patients are excluded; patients of childbearing potential should not become pregnant and should not father a child during treatment with gefitinib; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
- Signed informed consent according to institutional guidelines must be obtained prior to study entry
Exclusion Criteria:
- Patients with evidence of intramural hemorrhage on a scan obtained prior to enrollment or after enrollment, before treatment
- Patients with BSG must not be taking enzyme-inducing anticonvulsant drugs
- Patient must not be receiving any other anticancer or experimental drug therapy
- Patient must have no uncontrolled infection
- Patients with significant cardiac, hepatic, gastrointestinal, renal, pulmonary, or psychiatric disease are ineligible; patients with deep venous or arterial thrombosis within 6 weeks of study entry are ineligible
- Patients with disseminated disease are not permitted
- Patients with spinal disease requiring craniospinal radiation are not eligible
- Patients with completely resected supratentorial malignant gliomas patients are ineligible
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Treatment (gefitinib and radiation therapy)
Phase I portion: Patients receive oral gefitinib once daily. Treatment repeats every 4 weeks for 13 courses (1 year). Patients also receive standard brain irradiation once daily, 5 days a week, for 6 weeks beginning concurrently with initiation of the first course of gefitinib. Treatment continues in the absence of disease progression or unacceptable toxicity. Phase II portion: Once the MTD or the recommended Phase-II dose is determined, additional patients who have newly diagnosed BSG are treated at the MTD or the recommended Phase-II dose. |
Korrelatiiviset tutkimukset
Annettu suullisesti
Muut nimet:
Korrelatiiviset tutkimukset
Muut nimet:
Undergo standard brain irradiation
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Number of Participants in Phase I Stratum 1A With Dose-limiting Toxicities (DLT) Observed During the First 8 Weeks of Gefitinib Therapy
Aikaikkuna: Day 1 of gefitinib therapy to end of week 8
|
The dose limiting toxicity (DLT) analysis population consists of stratum 1A phase I participants who developed DLT during the maximum tolerated dose (MTD) estimation period (course 1 and 2) or who completed the MTD estimation period without DLTs.
DLTs observed during courses 1 and 2 were used to estimate the MTD based on the tradional 3+3 design, where a dose is considered a safe dose only when 0 out of 3, or at most 1 out of 6 patients has DLTs.
When two or more patients in a group of 2 to 6 patients had DLTs, then that dose level was considered to be too toxic.
|
Day 1 of gefitinib therapy to end of week 8
|
Median Progression-free Survival in Newly Diagnosed Brain Stem Gliomas
Aikaikkuna: Assessed pre-radiation, every 8 weeks for 13 courses of therapy, and then every 12 weeks
|
Progression-free survival is defined as the interval from intiation of treatment to the earliest of disease progression (tumor increase of 25% over baseline tumor measurement; appearance of new lesion(s); or progressive/worsening neurlogical status) or death for patients who failed or to the last date of follow-up for patients without failure
|
Assessed pre-radiation, every 8 weeks for 13 courses of therapy, and then every 12 weeks
|
Median Survival in Newly Diagnosed Brain Stem Gliomas
Aikaikkuna: Assessed from the start of therapy until three years after initiation of gefitinib therapy
|
Overall survival is defined as the interval from initiation of treatment to death or date of last contact for surviving patients
|
Assessed from the start of therapy until three years after initiation of gefitinib therapy
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Keskimääräinen kasvaimen suhde harmaaaineeseen mitattuna lähtötilanteessa
Aikaikkuna: Perustaso
|
Tässä tutkimuksessa yritetään karakterisoida positroniemissiotomografian hermokuvausparametreja.
Jokaiselle potilaalle tunnistettiin kasvaimen läpi kulkeva aksiaalinen kuva, joka sisälsi maksimiaktiivisuuden pikseliä kohden, joka vastaa suurinta fluorodeoksiglukoosin (FDG) ottoa, ja piirrettiin kiinnostava alue (ROI) kasvaimen FDG-määritelmän perusteella.
Keskimääräiset pikseliarvot kasvaimen ROI:ssa normalisoitiin normaalin harmaan aineen arvoilla kasvain/harmaa-aineen suhteen saamiseksi.
Jokaisella potilaalla on keskimääräinen kasvaimen ja harmaan aineen suhdearvo, ja näiden arvojen mediaani potilaiden kesken raportoidaan.
|
Perustaso
|
Change in Tumor Volume Measured on Fluid Attenuated Inversion Recovery (FLAIR) Imaging at Before the Protocol Therapy Started and at Two Weeks After Completion of Radiation
Aikaikkuna: Baseline and two weeks post completion of radiation
|
This study attempted to investigate in an exploratory manner the effect of treatment on changes in various neuroimaging variables.
In this particular objective, the study aimed to investigate how radiation+gefitinib affect the tumor volume.
Tumor volume is measured using Fluid Attenuated Inversion Recovery (FLAIR) before and after the radiation therapy.
|
Baseline and two weeks post completion of radiation
|
Change From Baseline in Volume Enhancing at Two Weeks After Completion of Radiation
Aikaikkuna: Baseline and two weeks post completion of radiation
|
This study attempted to investigate in an exploratory manner the effect of treatment on changes in various neuroimaging variables.
Neuroimaging changes may have some association with outcome (response,survival, etc.).
Volume enhancing is one parameter obtained from standard magnetic resonance imaging (MRI) studies of the brain.
|
Baseline and two weeks post completion of radiation
|
Change From Baseline in Diffusion Ratio at Two Weeks After Completion of Radiation
Aikaikkuna: Baseline and two weeks post completion of radiation
|
This study attempted to investigate in an exploratory manner the effect of treatment on changes in various neuroimaging variables.
Neuroimaging changes may have some association with outcome (response,survival, etc.).
Diffusion ratio is one parameter obtained from standard magnetic resonance imaging (MRI) studies of the brain.
|
Baseline and two weeks post completion of radiation
|
Change From Baseline in Perfusion Ratio at Two Weeks After Completion of Radiation
Aikaikkuna: Baseline and two weeks post completion of radiation
|
This study attempted to investigate in an exploratory manner the effect of treatment on changes in various neuroimaging variables.
Neuroimaging changes may have some association with outcome (response,survival, etc.).
Perfusion ratio is one parameter obtained from standard magnetic resonance imaging (MRI) studies of the brain.
|
Baseline and two weeks post completion of radiation
|
Mean Tumor to White Matter Ratio Measured at Baseline
Aikaikkuna: Baseline
|
This study attempts to characterize neuroimaging parameters from positron emission tomography.
For each patient, the axial image through the tumor containing the maximum activity per pixel corresponding to the highest FluoroDeoxyGlucose (FDG) uptake was identified and a region of interest (ROI) was drawn based on the FDG definition of the tumor.
The mean pixel values within the tumor ROI were normalized by those for normal white matter to provide ratios of tumor/gray matter.
Each patient has a mean tumor to white matter ratio value and the median of these values across patients is reported.
|
Baseline
|
Peak Serum Concentration of Gefitinib (Cmax)
Aikaikkuna: Week 2 of course 1
|
Week 2 of course 1
|
|
Elimination Half Life of Gefitinib (t1/2)
Aikaikkuna: Week 2 of course 1
|
Week 2 of course 1
|
|
Clearance of Gefitinib (Cl)
Aikaikkuna: Week 2 of course 1
|
Week 2 of course 1
|
|
Time of Maximum Clearance of Gefitinib (Tmax)
Aikaikkuna: Week 2 of course 1
|
Week 2 of course 1
|
|
Gefitinib Area Under the Concentration Curve From 0-24 Hours (AUC)
Aikaikkuna: Week 2 of course 1
|
Week 2 of course 1
|
|
Number of Patients With Epidermal Growth Factor Receptor (EGFR) Amplification
Aikaikkuna: Pre-treatment
|
Epidermal growth factor receptor (EFGR) is a protein found on the surface of cells to which epidermal growth factor (EGF) binds.
When EGF attaches to EGFR, it activates the enzyme tyrosine kinase, triggering reactions that cause the cells to grow and multiply.
|
Pre-treatment
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Jeffrey Geyer, Pediatric Brain Tumor Consortium
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Arvio)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Neoplasmat histologisen tyypin mukaan
- Neoplasmat
- Kasvaimet, rauhas- ja epiteelikasvaimet
- Neuroektodermaaliset kasvaimet
- Neoplasmat, sukusolut ja alkiot
- Kasvaimet, hermokudos
- Glioblastooma
- Glioma
- Astrosytooma
- Gliosarkooma
- Oligodendrogliooma
- Neoplasmat, neuroepiteliaaliset
- Farmakologisen vaikutuksen molekyylimekanismit
- Entsyymin estäjät
- Antineoplastiset aineet
- Proteiinikinaasin estäjät
- Gefitinib
Muut tutkimustunnusnumerot
- NCI-2012-03022 (Rekisterin tunniste: CTRP (Clinical Trial Reporting Program))
- U01CA081457 (Yhdysvaltain NIH-apuraha/sopimus)
- PBTC-007 (Muu tunniste: CTEP)
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Hoitamaton lapsuuden aivovarren gliooma
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RekrytointiGlioma | Brain MassYhdysvallat
-
Beijing Tiantan HospitalRekrytointiGlioma | Propofol | Auditory Event-related Potential (AERP) | Elektroenkefalogrammi (EEG) | Brain Network ConnectivityKiina
Kliiniset tutkimukset laboratoriobiomarkkerianalyysi
-
ORIOL BESTARDValmisMunuaisensiirto | CMV-infektioEspanja, Belgia
-
Mologic LtdUniversity College London Hospitals; Innovate UKTuntematon
-
University of MichiganNational Institute on Aging (NIA)Ilmoittautuminen kutsustaAlzheimerin tauti | Lievä kognitiivinen heikentyminen | Amnestinen lievä kognitiivinen häiriöYhdysvallat
-
Sonde HealthMontefiore Medical CenterAktiivinen, ei rekrytointi
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)Ei vielä rekrytointiaHIV-infektiot | B-hepatiitti
-
Boston University Charles River CampusNational Institute on Deafness and Other Communication Disorders (NIDCD)Rekrytointi
-
US Department of Veterans AffairsValmisKielihäiriöt | Afasia | PuhehäiriötYhdysvallat
-
Liao Jian AnRekrytointiPään ja kaulan syöpäTaiwan
-
Istituto per la Ricerca e l'Innovazione BiomedicaRekrytointi
-
University of VirginiaTuntematon